10 Resilient Stocks Defying Market Sentiment

5. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Recursion Pharmaceuticals grew its share prices for a fourth straight day on Monday, adding 9.59 percent to close at $6.40 apiece as investors repositioned portfolios ahead of its second quarter earnings results.

Based on its historical reporting dates, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) will announce the results of its performance in the first week of August 2025.

Investor excitement was further supported by a social media post by the company’s senior director, Peter Ray, about an ongoing drug candidate called REC-3565, which aims to treat relapsed or refractory B-cell lymphomas.

Now on Phase 1 trial, REC-3565 is being developed using Recursion Pharmaceuticals, Inc.’s (NASDAQ:RXRX) advanced AI platform, which is said would not conceive through traditional human design methods.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the few companies that earned the backing of technology giant Nvidia Corp., one of the key drivers of the Artificial Intelligence sector.